Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 7.8% – Should You Sell?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s stock price dropped 7.8% during trading on Tuesday . The company traded as low as $0.33 and last traded at $0.33. Approximately 39,393,920 shares changed hands during trading, an increase of 28% from the average daily volume of 30,856,506 shares. The stock had previously closed at $0.36.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on shares of Tonix Pharmaceuticals in a report on Monday, December 23rd. They issued a “hold” rating on the stock.

Tonix Pharmaceuticals Trading Down 9.8 %

The company’s fifty day moving average price is $0.23 and its 200-day moving average price is $0.37. The stock has a market cap of $60.72 million, a price-to-earnings ratio of -0.01 and a beta of 2.23. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. The business had revenue of $2.82 million during the quarter, compared to analysts’ expectations of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. On average, research analysts expect that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current fiscal year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.